Results 241 to 250 of about 107,280 (285)

Mechanisms of Mitochondrial Toxicity and Cytotoxicity Caused by Pseudomonas aeruginosa Pyocyanin in Human Nasal Epithelial Cells

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Pseudomonas aeruginosa is an opportunistic pathogen in cystic fibrosis‐related chronic rhinosinusitis (CF‐CRS) that produces phenazine metabolites pyocyanin and 1‐hydroxyphenazine (1‐HP), which may have detrimental effects on mitochondria, reactive oxygen species (ROS), Ca2+ signaling, and apoptosis.
Joel C. Thompson, April Park, Yobouet Ines Kouakou, Zoey A. Miller, Nabil F. Darwich, Nithin D. Adappa, James N. Palmer, Ryan M. Carey, Robert J. Lee   +8 more
wiley   +1 more source

Hub genes and diagnostic model associated with mitochondrial function in Alzheimer's disease

Animal Models and Experimental Medicine, EarlyView.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and mitochondrial dysfunction has been confirmed in AD patients and mouse models. However, the pathogenic genes associated with AD and early diagnostic methods based on mitochondrial function remain to be explored.
Xuchao Zhu, Ling Zhang, Chuan Qin
wiley   +1 more source

Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors. [PDF]

Clin Transl Oncol
Katsaraki K, Kontos CK, Ardavanis-Loukeris G, Tzovaras AA, Sideris DC, Scorilas A.   +5 more
europepmc   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis [PDF]

Turk J Haematol
Ataş Ü, Salim O, Iltar U, Yücel OK, Küçükdiler Eroğlu AH, Aslan V, Yıldırım M, Dedeoğlu Ö, Seçilmiş S, Ulaş T, Deveci B, Karaman Gulsaran S, Gedük A, Yaman F, Pınar İE, Maral S, Sarıcı A, Çelik S, Oğul H, Gülkan Özkan S, Gemici A, Güneş AK, Tombak A, Yavaşoğlu İ, Karakuş V, Cömert M, Toptaş T, Dal MS, Saba R, Kırkızlar HO, Mehtap Ö, Gündüz E, Özkalemkaş F, Albayrak M, Berber İ, Keklik M, Güler N, Özkan HA, Sevindik ÖG, Bolaman Z, Kurtoğlu E, Aylı M, Fıratlı Tuğlular T, Altuntaş F, Ündar L.   +44 more
europepmc   +1 more source

Porous Organic Frameworks‐Based Nanomaterials in Colorectal Cancer Therapy: From Drug Delivery to Personalized Nano‐Vaccine

Cancer Nexus, EarlyView.
ABSTRACT Colorectal cancer (CRC), as the second most common cause of cancer death worldwide, has seen a significant increase in its incidence rate in recent years. However, the current major clinical treatment methods, such as surgery, chemotherapy and radiotherapy, still have certain limitations and are difficult to achieve a complete cure.
Xiaoyu Song, Hao Zhang, Yinghui Wang, Chao Luo   +3 more
wiley   +1 more source

Proteasome Inhibitors

Dimopoulos, Meletios A, Terpos, Evangelos, Kastritis, Efstathios   +2 more
openaire   +2 more sources

Effect of histone deacetylase and proteasome inhibitors in glioma models

Luciana; id_orcid 0000-0002-2306-7959 Costa Furtado, Frank; id_orcid 0000-0002-2445-9380 Kruyt, Leticia Veras Costa-Lotufo   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proteasome Inhibitors

Materials and Methods, 2012
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
  +5 more sources